Altamira Therapeutics Ltd... (CYTO)
0.30
0.00 (0.00%)
At close: Dec 19, 2024, 9:00 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 1.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.82 |
| PE Ratio (ttm) | 0.16 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 724,295 |
| Avg. Volume (20D) | 135,377 |
| Open | 0.42 |
| Previous Close | 0.30 |
| Day's Range | 0.30 - 0.42 |
| 52-Week Range | 0.10 - 3.60 |
| Beta | undefined |
About CYTO
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA deliver...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 6, 2014
Employees 10
Stock Exchange NASDAQ
Ticker Symbol CYTO
Website https://altamiratherapeutics.com
7 months ago ·
Source
+19.58%
Altamira Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
9 months ago ·
Source
+35.84%
Altamira Therapeutics shares are trading higher after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.
